Optimal antithrombotic strategy in patients with atrial fibrillation after coronary stent implantation

Korean Circulation Journal

Volumn 41, Issue 10, 2011, Pages 578-582

  Jang, Sung Won ^a   Rho, Tai Ho ^a   Kim, Dong Bin ^a   Cho, Eun Joo ^a   Kwon, Beom June ^a   Park, Hun Jun ^a   Shin, Woo Seung ^a   Kim, Ji Hoon ^a   Lee, Jong Min ^a   Moon, Keon Woong ^a   Oh, Yong Seog ^a   Yoo, Ki Dong ^a   Youn, Ho Joong ^a   Lee, Man Young ^a   Chung, Wook Sung ^a   Seung, Ki Bae ^a   Kim, Jae Hyung ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

Angioplasty; Anticoagulants; Atrial fibrillation; Platelet aggregation inhibitors; Stents

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BARE METAL STENT; BLEEDING; COMORBIDITY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CORONARY STENT; DIABETES MELLITUS; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; RETROSPECTIVE STUDY; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; STENT THROMBOSIS; STROKE; SURVIVAL RATE; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 82055193614     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2011.41.10.578     Document Type: Article

References (17)

1. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006;48:854-906. (Pubitemid 44175743)
2. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002;288:2441-8. (Pubitemid 35340540)
3. Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2007:CD006186.
4. Lip GY, Karpha M. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline. Chest 2006;130:1823-7. (Pubitemid 46033440)
5. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70. (Pubitemid 32537350)
6. Ruiz-Nodar JM, Marin F, Hurtado JA, et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 2008;51:818-25. (Pubitemid 351255616)
7. Lee SW, Park SW, Kim YH, et al. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am J Cardiol 2007;100:1103-8.
8. Han Y, Li Y, Wang S, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009;157:733-9.
9. Yang TH, Kim DI, Kim JY, et al. Comparison of triple anti-platelet therapy (aspirin, clopidogrel, and cilostazol) and double anti-platelet therapy (aspirin and clopidogrel) on platelet aggregation in type 2 diabetic patients undergoing drug-eluting stent implantation. Korean Circ J 2009;39:462-6.
10. Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-12.
11. Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008;118:2029-37.
12. Sorensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009;374:1967-74.
13. Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 2007;50:309-15. (Pubitemid 47061504)
14. Suzuki S, Yamashita T, Kato T, et al. Incidence of major bleeding complication of warfarin therapy in Japanese patients with atrial fibrillation. Circ J 2007;71:761-5. (Pubitemid 46683370)
15. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002;287:1690-8. (Pubitemid 34289221)
16. Li T, Lange LA, Li X, et al. Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. J Med Genet 2006;43:740-4. (Pubitemid 44483917)
17. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005;352:2285-93. (Pubitemid 40740552)